A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.
Susan M. Domchek(University City Science Center), Robert H. Vonderheide(University of Pennsylvania), Mitch Raponi(Clovis Oncology (United States)), Heidi Giordano(Mayo Clinic in Arizona), Steven R. Alberts(North Central Cancer Treatment Group), Jeffrey D. Isaacson, Andrew Hendifar(Cedars-Sinai Medical Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Andrew R. Allen(Vanderbilt University), Ron Epelbaum(University of Bern), George P. Kim(Mayo Clinic in Arizona), Andrew V. Biankin(University of Glasgow), Lawrence P. Leichman(New York University), Robert R. McWilliams(Mayo Clinic in Arizona), Lindsey Rolfe, Rachna T. Shroff(University of Arizona)
Cited by 3
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k